RICHMOND, Calif. — October 30, 2025 — Leads & Copy — Sangamo Therapeutics, Inc. (Nasdaq: SGMO) will release its third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. A conference call will be held at 8:30 a.m. Eastern on Thursday, November 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events. A replay will be available following the conference call, accessible under Events.
Sangamo Therapeutics is dedicated to translating ground-breaking science into medicines. They transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment.
Investor Relations Contact: Louise Wilkie, ir@sangamo.com
Media Inquiries Contact: Melinda Hutcheon, media@sangamo.com
Source: Sangamo Therapeutics, Inc.
